Shares of Ibio Inc (NYSEMKT:IBIO) ended Tuesday session in red amid volatile trading. The shares closed down -0.004 points or -0.64% at $0.574 with 181,792.00 shares getting traded. Post opening the session at $0.57, the shares hit an intraday low of $0.56 and an intraday high of $0.60 and the price vacillated in this range throughout the day. The company has a market cap of $49.63 million and the numbers of outstanding shares have been calculated to be 89.11 million shares.
Ibio Inc (IBIO), a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The companys proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that is designed to improve the potency and duration of effect of prophylactic and therapeutic vaccines. Its therapeutic protein product candidates comprise IBIO-CFB03, a product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody.
Shares of XOMA Corp (NASDAQ:XOMA) ended Tuesday session in red amid volatile trading. The shares closed down -0.028 points or -4.07% at $0.660 with 1.05 million shares getting traded. Post opening the session at $0.68, the shares hit an intraday low of $0.64 and an intraday high of $0.69 and the price vacillated in this range throughout the day. The company has a market cap of $82.96 million and the numbers of outstanding shares have been calculated to be 120.59 million shares.
XOMA Corp (XOMA) announced it will host a webcast and conference call on September 15, 2016, at 1:30 p.m. PDT (4:30 p.m. EDT), to provide an update on the ongoing XOMA 358 Phase 2 proof-of-concept clinical program in congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS), two rare medical conditions resulting from abnormal insulin secretion.
The presentation slides and webcast can be accessed via the Investors and Media section of XOMA’s website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on December 15, 2016. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international) with the passcode 75822110.